Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy
- 1 October 2018
- Vol. 36 (45) , 6744-6751
Abstract
No abstract availableKeywords
Funding Information
- Public Health Service
- National Institute of Allergy and Infectious Diseases
- Hatch and Animal Health Funds
- Egyptian Government Scholarship
This publication has 39 references indexed in Scilit:
- Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)The Lancet, 2018
- Broadly Protective Adenovirus-Based Multivalent Vaccines against Highly Pathogenic Avian Influenza Viruses for Pandemic PreparednessPLOS ONE, 2013
- Production of adenovirus vectors and their use as a delivery system for influenza vaccinesExpert Opinion on Biological Therapy, 2010
- Bovine Adenoviral Vector–based H5N1 Influenza Vaccine Overcomes Exceptionally High Levels of Pre-existing Immunity Against Human AdenovirusMolecular Therapy, 2008
- A Broadly Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza VirusesThe Journal of Infectious Diseases, 2008
- Innate Immune Response to Adenoviral Vectors Is Mediated by both Toll-Like Receptor-Dependent and -Independent PathwaysJournal of Virology, 2007
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus VectorThe Journal of Infectious Diseases, 2006
- Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in miceThe Lancet, 2006
- Development of nonhuman adenoviruses as vaccine vectorsVaccine, 2006
- Heterosubtypic Immunity against Human Influenza A Viruses, Including Recently Emerged Avian H5 and H9 Viruses, Induced by FLU–ISCOM Vaccine in Mice Requires both Cytotoxic T-Lymphocyte and Macrophage FunctionCellular Immunology, 2001